Glaxo’s Alli Advances Toward OTC Sale With “Approvable” Letter
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline's proposed Rx-to-OTC switch of the weight-loss drug Alli (orlistat 60 mg) is "approvable," according to a letter from FDA received by the firm April 6
You may also be interested in...
Switch Case Study: GSK Alli Review Shows FDA Data Mining In Context
[F-D-C Reports' Pharmaceutical Approvals Monthly dissects drug reviews by FDA. While each drug stands or fails alone, a specific review can provide valuable insight into FDA's interpretation of data, policy and guidance documents, recurring controversies and resolution of internal disagreement. This story completes a two-part feature on alli.
Alli Approved OTC For Weight Loss With “Goal Oriented” Indication
FDA's approved labeling for GlaxoSmithKline's first-in-class nonprescription weight-loss drug alli (orlistat 60 mg) emphasizes a "goal oriented" indication as opposed to a six-month duration of use as originally proposed
Lancet article questions orlistat
"Antiobesity drug trials powered to show clinically important reductions in major obesity-related morbidity and mortality should be required either before these drugs are approved for widespread use or as a condition of ongoing approval, authors of an article in the Jan. 6 Lancet say. Raj S. Padwal, M.D., et al. review data on orlistat, sibutramine and rimonabant, noting all three are "limited by modest efficacy and low rates of persistence with treatment." Drugs "that improve surrogate endpoints such as weight loss might not necessarily improve endpoints judged to be more clinically relevant," so higher-powered trials are needed to adequately gauge risk/benefit, they say. Aside from bariatric surgery, "which is neither a feasible nor a desirable population-based treatment for obesity, no intervention has produced consistent effective long-term weight loss," the authors note. GlaxoSmithKline received an "approvable" letter in April for alli, a 60 mg dose of orlistat, for OTC sale to consumers 18 years old and up (1"The Tan Sheet" April 10, 2006, p. 8)...